Volume 147, Issue 3, Pages 637-645 (September 2014) CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan- Based Therapy for Stage III Colon Cancer  Stacey Shiovitz, Monica M. Bertagnolli, Lindsay A. Renfro, Eunmi Nam, Nathan R. Foster, Slavomir Dzieciatkowski, Yanxin Luo, Victoria Valinluck Lao, Raymond J. Monnat, Mary J. Emond, Nancy Maizels, Donna Niedzwiecki, Richard M. Goldberg, Leonard B. Saltz, Alan Venook, Robert S. Warren, William M. Grady  Gastroenterology  Volume 147, Issue 3, Pages 637-645 (September 2014) DOI: 10.1053/j.gastro.2014.05.009 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 Molecular characteristics in CIMP-positive and CIMP-negative tumors. CIMP-positive tumors were more often MMR-deficient, BRAF-mutated, and KRAS-wild-type as compared with CIMP-negative tumors. The frequencies of TP53 mutations were similar in the CIMP-positive and CIMP-negative groups. Gastroenterology 2014 147, 637-645DOI: (10.1053/j.gastro.2014.05.009) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 Survival in CIMP-positive and CIMP-negative CRC: (A) Overall survival and (B) disease-free survival. Patients with CIMP-positive tumors had significantly worse overall survival compared with patients with CIMP-negative tumors. CIMP status alone was not associated with disease-free survival. Gastroenterology 2014 147, 637-645DOI: (10.1053/j.gastro.2014.05.009) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Interaction of CIMP status and treatment arm on survival: (A) Overall survival and (B) disease-free survival. In the 2-way interaction model between treatment arm and CIMP status, of patients treated with FU/LV, CIMP-positivity was associated with worse overall survival. However, in patients treated with IFL, there was no overall survival difference between CIMP-positive and CIMP-negative tumors. Disease-free survival results were similar. Gastroenterology 2014 147, 637-645DOI: (10.1053/j.gastro.2014.05.009) Copyright © 2014 AGA Institute Terms and Conditions

Figure 4 Interaction of CIMP status and MMR status on survival: (A) Overall survival and (B) disease-free survival. In the 2-way interaction model between MMR and CIMP, patients with CIMP-positive, MMR-D tumors had improved overall survival compared with CIMP-positive, MMR-I tumors. However, there was no significant overall survival difference by MMR status within patients with CIMP-negative tumors. Disease-free survival results were similar. Gastroenterology 2014 147, 637-645DOI: (10.1053/j.gastro.2014.05.009) Copyright © 2014 AGA Institute Terms and Conditions

Figure 5 Combined interaction effect on overall survival of CIMP, MMR, and treatment: by treatment arm (A) FU/LV treatment arm, (B) IFL treatment arm; by CIMP status: (C) CIMP-negative, (D) CIMP-positive. In the 3-way interaction model between CIMP, MMR, and chemotherapy treatment arm, patients with CIMP-negative tumors treated with FU/LV had worse overall survival if they were MMR-D (vs MMR-I). The reverse is true for CIMP-positive patients, where a benefit from FU/LV was observed in MMR-D vs MMR-I tumors. In the IFL arm, there was no significant difference by CIMP and MMR status. Gastroenterology 2014 147, 637-645DOI: (10.1053/j.gastro.2014.05.009) Copyright © 2014 AGA Institute Terms and Conditions